Amgen

Amgen

Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company founded in 1980 with headquarters in Thousand Oaks, California.

Amgen works in discovery, development and manufacturing of human therapeutics for treatment of illnesses in the areas of oncology, hematology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience.

Products

Amgen’s products include the following: Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine)and Aimovig.

The top protein-based therapeutics include Neulasta, Neupogen, Aranesp, Epogen and Enbrel. ENBREL is on the market in the United States to treat rheumatoid arthritis, plaque psoriasis and psoriatic arthritis. Neulasta treats people receiving chemotherapy to reduce infection. Aranesp and EPOGEN are used to treat anemia in different circumstances including chronic kidney disease. Cinacalcet (Sensipar in US and Mimpara in Europe) is used for secondary hyperparathyroidism with chronic kidney disease. XGEVA is for prevention of skeletal related events in patients with bone metastases from solid tumors. Prolia is used to treat postmenopausal women with osteoporosis at risk of fracture . NEUPOGEN is a recombinant-methionyl human granulocyte colony-stimulating factor (G-CSF) to reduce chance of infection due to low white blood cell count for cancer patients receiving chemotherapy . Aimovig was FDA approved in 2018 and will be marketed in partnership with Novartis as a drug to prevent migraines .

Clinical Trials

The following Amgen therapeutics are candidates in Phase III clinical trials: Erenumab for episodic migraine; Aranesp for myelodysplastic syndromes; BLINCYTO for acute lymphoblastic leukemia (ALL); ENBREL for psoriatic arthritis and rheumatoid arthritis remission; IMLYGIC for metastatic melanoma; Kyprolis for multiple myeloma; Prolia for glucocorticoid-induced osteoporosis; Repatha for hyperlipidemia; XGEVA for delay or prevention of bone metastases in breast cancer and also for the treatment of cancer-related bone damage in patients with multiple myeloma; Vectibix for metastatic colorectal cancer (mCRC); Omecamtiv mecarbil for chronic heart failure, and EVENITY for postmenopausal osteoporosis and male osteoporosis.

The following Amgen therapeutics are candidates in Phase II clinical trials: BLINCYTO for diffuse Large B-Cell Lymphoma (DLBCL) and relapsed/refractory Philadelphia positive (R/R Ph+) and minimal residual disease of ALL; Erenumab for Chronic migraine; AMG 157 for asthma and atopic dermatitis; AMG 520 for Alzheimer's disease, and AMG 899 for dyslipidemia.

The following Amgen therapeutics are candidates in Phase I clinical trials: IMLYGIC for various cancer types; KYPROLIS for small-cell lung cancer; Oprozomib for multiple myeloma; AMG 176 for various cancer types; AMG 211 for various cancer types; AMG 224 for multiple myeloma, and AMG 301 for migraine. The Company's product candidates in Phase I also include AMG 330 for acute myeloid leukemia; AMG 420 for multiple myeloma; AMG 557 for systemic lupus erythematosus; AMG 570 for systemic lupus erythematosus; AMG 592 for inflammatory diseases; AMG 820 for various cancer types, and AMG 986 for heart failure.

Timeline

Funded Companies

Company
Description
Website
Industry
Location

A biopharmaceutical company focused on discovery and development of small-molecule drugs to treat genetic and rare diseases

miRagen is a clinical stage biopharmaceutical company developing innovative microRNA-targeting therapies to improve human health.

DNA sequencing company specializing in rapid long-read sequencing through nanopores.

A biopharmaceutical company focused on the discovery and development of immunotherapy of cancer

Gamida Cell is a biotechnology company developing cell therapies for treating cancer and hematologic diseases.

A biopharmaceutiical company discovering, developing and manufacturing therapeutics for the treatment of canccer

A biopharmaceutical company focused on the discovery and development of epigenetic medicines to treat cancer and other disease

A biopharmaceutical company developing oral therapeutics for the treatment of mineral metabolism and metabolic disorders

A company developing technologies in protein-based therapeutics

A company that develops therapeutic oral medicines for the treatment of cancer and inflammatory diseases

A biotechnology company that develops therapeutic antibodies for treating infectious diseases and inflammation

A consulting and research services company for science companies

A biotechnology company developing peptides and antibodies for inflammation and autoimmunity

A biopharmaceutical company developing treatments for neuroendocrine, metabolic and immune disorders

A company designing bio-therapeutics for endocrine and other disorders

A company developing cancer therapeutics

Opsona Therapeutics is a Dublin-based company.

SiteOne Therapeutics is a Bozeman, Montana-based company.

19 Results
Page 1 of 1
Results per page:
Powered by Golden Research Engine

People

Name
Role
LinkedIn

Abid AZAM

Employee

Adam Hardin

Employee

Aditya Nag

Employee

aditya narula

Employee

Ahilaa Kamuthurai

Employee

AKASH ARYA

Employee

Alan Jamijian

Employee

Albert Hidayat

Employee

Alberto Chan

Employee

Alejandro Diaz

Employee

Alekhya Narni

Employee

Aleksander Malinowski

Employee

Alessandro Seveso

Employee

Alex Marzo

Employee

Alex Roman

Employee

Alex Shoshitaishvili

Employee

Alexander Julian Veach

Employee

Alfonso Kondo

Employee

Alfredo Zambonini

Employee

Alice Augustine

Employee

Alina Karimova

Employee

Alix Taffle

Employee

Allen Walker

Employee

Allison S

Employee

Alok Gandhi

Employee

Page 1 of 27

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
BioSpace
May 26, 2020
BioSpace
Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that David Lacey, M.D. has joined the Company's Board of Directors
Nick Paul
May 14, 2020
FierceBiotech
Amgen's KRAS inhibitor has shown limited efficacy in early testing in patients with cancers outside of the lung. The study linked the high dose of AMG-510 to a response rate of 12% in colorectal cancer patients and found similar efficacy in other solid tumor types.
BioSpace
May 8, 2020
BioSpace
- Amgen (NASDAQ:AMGN) and Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for omecamtiv mecarbil, a novel selective cardiac myosin activator, also known as a cardiac myotrope, 1 being developed for the potential treatment of chronic heart failure with reduced ejection fraction (HFrEF). Fast Track designation may p
Reuters
February 22, 2020
@bsindia
As Lundbeck enters the crowded market, it hopes to carve a niche for itself through its dosing frequency
Amgen
September 13, 2019
www.prnewswire.com:443
THOUSAND OAKS, Calif., Sept. 13, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Bank of America Merrill Lynch Global Healthcare Conference at...
Jessica Galang
September 12, 2019
BetaKit
Toronto Innovation Acceleration Partners, formerly MaRS Innovation, has announced a partnership with Amgen, its first since rebranding.
August 28, 2019
news.yahoo.com
Patent cliffs and pipeline risks are among the reasons these biologic drug specialists are attractively priced today.
Marie Szaniszlo
April 26, 2019
Boston Herald
Two pharmaceutical companies have agreed to pay a total of nearly $125 million to resolve allegations that they paid kickbacks through co-pay assistance foundations, federal prosecutors said. Astellas Pharma U.S. and Amgen agreed to pay $124.75 million to settle charges they violated the False Claims Act by illegally paying the co-pays to induce Medicare patients
October 25, 2018
nytimes.com
The drug maker cut the list price of the drug Repatha by 60 percent in an effort to increase sales, which have been meager.

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.